[go: up one dir, main page]

PT2625172T - Novas formas cristalinas do sal de sódio do ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético - Google Patents

Novas formas cristalinas do sal de sódio do ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético

Info

Publication number
PT2625172T
PT2625172T PT117706226T PT11770622T PT2625172T PT 2625172 T PT2625172 T PT 2625172T PT 117706226 T PT117706226 T PT 117706226T PT 11770622 T PT11770622 T PT 11770622T PT 2625172 T PT2625172 T PT 2625172T
Authority
PT
Portugal
Prior art keywords
pyridin
ylamino
trifluoromethyl
cyclohexyl
phenyl
Prior art date
Application number
PT117706226T
Other languages
English (en)
Inventor
Liang Jessica
Prashad Mahavir
Allen Sutton Paul
J Girgis Michael
Bernard Villhauer Edwin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44802409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2625172(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2625172T publication Critical patent/PT2625172T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT117706226T 2010-10-07 2011-10-05 Novas formas cristalinas do sal de sódio do ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético PT2625172T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39088810P 2010-10-07 2010-10-07

Publications (1)

Publication Number Publication Date
PT2625172T true PT2625172T (pt) 2017-03-10

Family

ID=44802409

Family Applications (2)

Application Number Title Priority Date Filing Date
PT117706226T PT2625172T (pt) 2010-10-07 2011-10-05 Novas formas cristalinas do sal de sódio do ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético
PT131977142T PT2781516T (pt) 2010-10-07 2011-10-05 Novas formas cristalinas do sal de sódio do ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT131977142T PT2781516T (pt) 2010-10-07 2011-10-05 Novas formas cristalinas do sal de sódio do ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético

Country Status (26)

Country Link
US (2) US8829194B2 (pt)
EP (2) EP2625172B1 (pt)
JP (1) JP6093703B2 (pt)
KR (2) KR20130115277A (pt)
CN (1) CN103153981B (pt)
AR (1) AR083317A1 (pt)
AU (1) AU2011312185B2 (pt)
BR (1) BR112013008355A2 (pt)
CA (1) CA2813736C (pt)
CL (1) CL2013000929A1 (pt)
CO (1) CO6710909A2 (pt)
EC (1) ECSP13012608A (pt)
ES (2) ES2618411T3 (pt)
GT (1) GT201300089A (pt)
IL (1) IL225532A0 (pt)
MA (1) MA34645B1 (pt)
MX (1) MX2013003835A (pt)
NZ (1) NZ608557A (pt)
PE (1) PE20140337A1 (pt)
PH (1) PH12013500659A1 (pt)
PL (2) PL2781516T3 (pt)
PT (2) PT2625172T (pt)
RU (1) RU2612556C2 (pt)
SG (1) SG188586A1 (pt)
TW (1) TW201217360A (pt)
WO (1) WO2012047948A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ608557A (en) * 2010-10-07 2015-02-27 Novartis Ag New crystalline forms of the sodium salt of (4-{ 4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl} - cyclohexyl)-acetic acid
CN103796995B (zh) * 2011-09-12 2015-10-07 霍夫曼-拉罗奇有限公司 N-(5-环烷基-或5-杂环基-)-吡啶-3-基甲酰胺
WO2013163508A1 (en) * 2012-04-27 2013-10-31 Novartis Ag Tetrahydropyran dgat1 inhibitors
CA2870336A1 (en) * 2012-04-27 2013-10-31 Novartis Ag Cyclic bridgehead ether dgat1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
KR101646716B1 (ko) 2016-02-15 2016-08-08 서성환 조립식 나선계단용 스페이서 및 이를 이용한 조립식 나선계단
WO2020131649A1 (en) * 2018-12-20 2020-06-25 Merck Sharp & Dohme Corp. Novel crystalline forms of an nrtti compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
ATE442365T1 (de) 2003-05-20 2009-09-15 Novartis Pharma Gmbh N-acyl stickstoffheterocyclen als liganden von peroxisom-proliferator-aktivierten rezeptoren
US20050226906A1 (en) 2004-04-08 2005-10-13 Micro Nutrient, Llc Nutrient system for individualized responsive dosing regimens
PT2402319T (pt) 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
JP2010512410A (ja) * 2006-12-11 2010-04-22 ノバルティス アーゲー 心筋虚血を予防または処置するための方法
NZ608557A (en) * 2010-10-07 2015-02-27 Novartis Ag New crystalline forms of the sodium salt of (4-{ 4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl} - cyclohexyl)-acetic acid

Also Published As

Publication number Publication date
CA2813736A1 (en) 2012-04-12
AR083317A1 (es) 2013-02-13
EP2781516B1 (en) 2016-12-07
PL2625172T3 (pl) 2017-07-31
AU2011312185A1 (en) 2013-04-04
KR20180011337A (ko) 2018-01-31
IL225532A0 (en) 2013-06-27
PE20140337A1 (es) 2014-03-13
KR20130115277A (ko) 2013-10-21
US20140343102A1 (en) 2014-11-20
ECSP13012608A (es) 2013-07-31
GT201300089A (es) 2014-12-30
KR101900652B1 (ko) 2018-09-19
PH12013500659A1 (en) 2021-03-03
ES2618411T3 (es) 2017-06-21
CL2013000929A1 (es) 2013-09-27
MX2013003835A (es) 2013-06-28
EP2781516A3 (en) 2014-10-15
CN103153981A (zh) 2013-06-12
CO6710909A2 (es) 2013-07-15
JP6093703B2 (ja) 2017-03-08
BR112013008355A2 (pt) 2016-06-14
PL2781516T3 (pl) 2017-05-31
EP2625172B1 (en) 2016-12-07
NZ608557A (en) 2015-02-27
AU2011312185B2 (en) 2015-07-02
TW201217360A (en) 2012-05-01
MA34645B1 (fr) 2013-11-02
RU2612556C2 (ru) 2017-03-09
US20130184311A1 (en) 2013-07-18
EP2625172A1 (en) 2013-08-14
CA2813736C (en) 2020-03-24
RU2013120549A (ru) 2014-11-20
WO2012047948A1 (en) 2012-04-12
EP2781516A2 (en) 2014-09-24
US8829194B2 (en) 2014-09-09
SG188586A1 (en) 2013-04-30
ES2618426T3 (es) 2017-06-21
CN103153981B (zh) 2017-10-10
JP2013539755A (ja) 2013-10-28
PT2781516T (pt) 2017-03-15

Similar Documents

Publication Publication Date Title
PT2625172T (pt) Novas formas cristalinas do sal de sódio do ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético
IL295518B1 (en) Heterocyclic compounds used as pdk1 inhibitors
SMT201600174B (it) Forme solide di acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]diossol-5-il)ciclopropancarbossammido)-3-metilpiridin-2-il)benzoico
PL2623497T3 (pl) Sól megluminowa 6-fluoro-3-hydroksy-2-pirazynokarboksamidu
ZA201202530B (en) Heterocyclic sulfonamide derivatives useful as mek inhibitors
ZA201308086B (en) Derivatives of 1-anino-2-cyclopropylboronic acid
IL222348A0 (en) Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate
HUE054438T2 (hu) Video deblokkolás belsõ PCM (IPCM) kódolási módhoz
SI2623498T1 (sl) Natrijeva sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida
HUE052128T2 (hu) Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására
HUE038042T2 (hu) PPAR helyettesítõ tiazolidindion sók metabolikus betegségek kezelésére
IL230127A0 (en) Amino-propionic acid derivatives, modified in position 3 (thiazole-4-carbonyl) or in (thiazole-2-carbonyl) and their use as pharmaceuticals
IL221325A0 (en) Salt of fused heterocyclic derivative and crystal thereof
IL214518A0 (en) Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as dhodh inhibitor
IL214517A0 (en) Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
SI2462098T1 (sl) Postopek priprave derivatov 1-(2-halobifenil-4-il)-ciklopropankarboksilne kisline
IL230468B (en) Crystalline form of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide
IL225717A0 (en) Arylsulfonamide salts as ccr3 antagonists
IL209837A0 (en) Sulfonate salts of flupirtine
IL232170A0 (en) Heterocyclic carboxamides are useful as phosphodiesterase type 10a inhibitors
IL225680A0 (en) Process for preparing 3-(6-amino-pyridin-3-yl)2-acrylic acid derivatives
PL2943488T3 (pl) Postacie soli megluminowej kwasu 2-((1r,4r)-4-(4-(5-(benzoksazol-2-iloamino)pirydyn-2-ylo)fenylo)cykloheksylo)octowego i ich zastosowania jako inhibitory dgat1
HK1169829A (en) Heterocyclic sulfonamide derivatives useful as mek inhibitors
PL390622A1 (pl) Sposób wytwarzania soli sodowej kwasu D-2-(2-metylofenoksy) propionowego
HK1184140A (en) Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives